ID
103
Cancer Name
Lung Large Cell Carcinoma (Non-Smoker Pathway)
Main Grouping
Respiratory
Organ System
Lungs
Cell Origin
Epithelial (large undifferentiated)
Pathways Affected
Lung large cell carcinoma in the non-smoker pathway involves a pathway landscape dominated by receptor tyrosine kinase driver alterations (EGFR, ALK, MET, RET, ROS1) rather than the tobacco carcinogen-induced TP53/KRAS pathways of smoking-related LCC, with downstream PI3K/AKT/mTOR, MAPK/ERK, STAT3, and RAS/RAF/MEK proliferative survival signaling, plus autophagy/AMPK pathway relevant to the SIRT1/AMPK-driven autophagy mechanism confirmed for quercetin in H1299 large cell lung carcinoma.
The EGFR/PI3K/AKT/mTOR pathway is the most therapeutically relevant and most frequently altered pathway in never-smoker LCC: EGFR activating mutations (~15-40% of never-smoker NSCLC/LCC) — predominantly exon 19 in-frame deletions (del746-750) and exon 21 L858R point mutation — create a constitutively active EGFR kinase that no longer requires EGF ligand binding for activation; constitutive EGFR kinase activity phosphorylates downstream adapter proteins including GRB2/SOS (activating RAS), PI3K p85 (activating PIP3/AKT), and STAT3/5; EGFR-driven PI3K/AKT/mTOR: PI3K generates PIP3 recruiting AKT; AKT activates mTORC1 (through TSC1/TSC2 inhibition) creating constitutive cap-dependent translation of cyclin D1, c-MYC, HIF-1alpha, and VEGF; AKT also inactivates FOXO1/3/4 (suppressing p27 and BIM) and activates MDM2 (suppressing p53); quercetin was confirmed to inhibit PI3K/AKT in lung cancer cell models targeting the EGFR-driven PI3K/AKT pathway dominant in never-smoker LCC; EGCG inhibits EGFR kinase activity and downstream PI3K/AKT in lung cancer cell models; curcumin inhibits EGFR and PI3K/AKT in lung cancer cell models.
The ALK fusion/STAT3/MAPK pathway is the second most important driver in never-smoker LCC: ALK fusions (predominantly EML4-ALK, chromosomal inversion inv(2)(p21p23) creating the echinoderm microtubule-associated protein-like 4 (EML4) fused to the anaplastic lymphoma kinase (ALK) intracellular kinase domain) occur in approximately 5-13% of never-smoker NSCLC including LCC; the EML4-ALK fusion protein is constitutively dimerized and kinase-active (the EML4 coiled-coil domain drives constitutive ALK kinase dimerization independent of ligand); constitutive ALK kinase activates: STAT3 (through direct JAK-like ALK STAT3 phosphorylation at Y705 driving SHH, BCL-2, cyclin D1, and c-MYC expression); PI3K/AKT (through IRS1/IRS4 adapter recruitment to phosphorylated ALK); MAPK/ERK (through GRB2/SOS/RAS activation from phosphorylated ALK); quercetin inhibits STAT3 in lung cancer cell models targeting the ALK-driven STAT3 activation; curcumin inhibits STAT3 in ALK-expressing lung cancer cell models; EGCG inhibits STAT3 and ALK downstream signaling.
The autophagy/SIRT1/AMPK pathway is particularly relevant to non-smoker LCC through the confirmed mechanism of quercetin's action in H1299 (p53-null large cell lung carcinoma) cells: quercetin was confirmed to induce pro-apoptotic autophagy through SIRT1/AMPK signaling in H1299 and A549 lung cancer cells (PMC8088950); SIRT1 (sirtuin 1, NAD+-dependent deacetylase) deacetylates and activates AMPK (AMP-activated protein kinase); AMPK activation phosphorylates ULK1 (autophagy-initiating kinase) driving autophagosome formation confirmed by TEM; the autophagic flux then triggers pro-apoptotic mitochondrial pathway activation; in never-smoker LCC, AMPK is frequently silenced through LKB1/STK11 inactivating mutations (~5-15% of NSCLC, enriched in never-smokers) — quercetin activation of SIRT1/AMPK may restore autophagic flux in LKB1-deficient never-smoker LCC cells.
Description
Lung large cell carcinoma (LCC) in the non-smoker pathway is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) defined by the absence of squamous, glandular, or neuroendocrine differentiation by histology, immunohistochemistry, and molecular profiling, occurring in never-smokers (fewer than 100 cigarettes lifetime) or minimal/former smokers. LCC represents approximately 5 to 10 percent of all NSCLC — corresponding to approximately 11,000 to 22,000 US cases annually from an estimated 236,000+ total lung cancer diagnoses. The proportion of LCC occurring in never-smokers is estimated at approximately 15 to 25 percent of all LCC cases, reflecting the global lung cancer in never-smokers (LCINS) burden — LCINS represents approximately 15 to 25 percent of all lung cancer and would rank as the 7th most common cause of cancer mortality globally if counted separately.
The non-smoker LCC pathway is characterized by a lower tumor mutational burden (TMB) and a distinct oncogenic driver landscape compared to smoking-related LCC: EGFR mutations are substantially enriched in never-smokers (approximately 15-40% of never-smoker NSCLC including LCC, versus approximately 5% in smokers); ALK fusions are also enriched (~5-13% vs <1-2% in heavy smokers); and KRAS mutations follow a different allelic spectrum (G12C enriched in smokers, G12D more prevalent in never-smokers with potentially different sensitivity profiles); STK11 inactivating mutations, PIK3CA mutations, METex14 skipping mutations, RET fusions, and ROS1 fusions complete the non-smoker driver landscape.
LCC in never-smokers tends to present at advanced stages (stage IIIB/IV at diagnosis in approximately 60-75% of cases) because symptoms are often absent until the tumor is large or metastatic. Brain metastasis at diagnosis or during disease course is particularly prevalent, occurring in approximately 30-50% of LCC patients. Overall 5-year survival for stage IV LCC is approximately 5 to 10 percent without driver mutation identification; non-smoker LCC with EGFR mutation may have improved outcomes given receptor tyrosine kinase-driven biology.
Environmental exposures established as risk factors for never-smoker lung cancer include: PM2.5 fine particulate matter (generating reactive oxygen species and DNA oxidative damage); radon decay products (alpha particle ionizing radiation); cooking oil fumes (high-temperature heated cooking generating aldehydes, acrolein, benzopyrene — particularly elevated in traditional East Asian open-wok cooking); asbestos fibers; indoor arsenic from contaminated water/soil; and second-hand smoke creating specific oxidative mutational signatures.
Published laboratory research confirms quercetin from onions induced pro-apoptotic autophagy and mitochondria-dependent apoptosis in H1299 (p53-null, large cell lung carcinoma cell line) and A549 human lung cancer cells via SIRT1/AMPK signaling confirmed — cell viability inhibited dose-dependently; LC3-II, beclin 1 upregulated; autophagosomes observed by TEM and LC3 immunofluorescence confirmed (PMC8088950) — directly applicable to non-smoker LCC.
Plant-Based Description
Whole-food plant-based dietary patterns provide phytochemicals with confirmed activity in lung cancer cell lines directly applicable to lung large cell carcinoma in the non-smoker pathway. Quercetin from onions and kale was confirmed to inhibit cell viability dose-dependently in H1299 (p53-null human large cell lung carcinoma — the most directly relevant cell line to LCC) and A549 human lung cancer cells; induced pro-apoptotic autophagy via SIRT1/AMPK signaling confirmed; induced mitochondria-dependent apoptosis confirmed by Western blot; LC3-II, beclin 1 upregulated confirmed; autophagosomes observed by TEM and LC3 immunofluorescence confirmed (PMC8088950) — directly in the H1299 large cell lung carcinoma cell line; quercetin also inhibits EGFR/PI3K/AKT targeting the EGFR driver mutations enriched in never-smoker LCC; curcumin inhibits EGFR, STAT3, PI3K/AKT, and NF-kB in lung cancer cell models; EGCG inhibits EGFR and ALK downstream signaling; sulforaphane activates Nrf2 targeting PM2.5/air pollutant oxidative DNA damage driving never-smoker LCC.
Plant Chemistry Detail
Quercetin from onions, kale, and apples has confirmed activity directly in H1299 human large cell lung carcinoma cells in a published study (PMC8088950 — "Quercetin induces pro-apoptotic autophagy via SIRT1/AMPK signaling pathway in human lung cancer cell lines A549 and H1299 in vitro") — H1299 is a p53-null human large cell lung carcinoma cell line derived from a lymph node metastasis, making this the most directly applicable published quercetin study to lung large cell carcinoma. In this confirmed study: quercetin inhibited cell viability of H1299 large cell lung carcinoma and A549 lung cancer cells dose-dependently confirmed by CCK-8 assay; quercetin induced mitochondria-dependent apoptosis in both cell lines confirmed by Western blot of apoptotic proteins; pro-apoptotic autophagy induced — quercetin promoted expression of LC3-II (autophagosome membrane marker) and beclin 1 (autophagy initiator) and suppressed p62/SQSTM1 (autophagy cargo receptor — p62 decrease confirms completion of autophagic flux) confirmed by Western blot; LC3-II, beclin 1, Atg5, Atg7, and Atg12 mRNA levels upregulated by quercetin treatment confirmed by RT-PCR; autophagosomes directly observed by transmission electron microscopy (TEM) confirmed; autophagosomes observed by LC3 immunofluorescence confirmed; SIRT1 protein levels dose-dependently elevated confirmed by Western blot — SIRT1 (sirtuin 1, NAD+-dependent deacetylase) is a key upstream activator of AMPK through LKB1 deacetylation and AMPK phosphorylation; pAMPK/AMPK ratio dose-dependently elevated by quercetin confirmed — AMPK phosphorylates ULK1 driving autophagosome formation; autophagy inhibitor 3-methyladenine (3-MA) effectively inhibited quercetin-induced apoptosis confirmed — establishing that autophagy is required for quercetin-mediated apoptosis in LCC cells; SIRT1 inhibitor EX527 and siRNA knockdown attenuated quercetin-induced autophagy confirmed — establishing SIRT1 as the upstream activator in quercetin's mechanism.
Curcumin from turmeric inhibits EGFR kinase in lung cancer cell models — directly targeting the EGFR driver mutations enriched in never-smoker LCC (~15-40%); curcumin inhibits STAT3 Y705 phosphorylation in lung cancer cell models targeting the ALK fusion-driven constitutive STAT3 activation (~5-13% never-smoker LCC); curcumin inhibits PI3K/AKT and mTOR in lung cancer cell models; curcumin inhibits NF-kB reducing survival gene expression. EGCG from green tea inhibits EGFR by directly binding the EGFR ATP-binding site — reducing constitutive EGFR kinase activity from EGFR-mutant never-smoker LCC; EGCG inhibits ALK downstream STAT3 and PI3K/AKT signaling. Sulforaphane from cruciferous vegetables activates Nrf2/ARE — directly countering the PM2.5/air pollutant/cooking fume oxidative DNA damage and ROS generation that drives never-smoker lung carcinogenesis; sulforaphane induces NQO1, HMOX1, and glutathione-S-transferases through Nrf2 in lung epithelial cells. Apigenin inhibits EGFR and STAT3 in lung cancer cell models. Resveratrol inhibits SIRT1/mTOR and induces autophagy in lung cancer cell models.
Nutritional Focus
Nutritional focus in lung large cell carcinoma in the non-smoker pathway targets the receptor tyrosine kinase drivers enriched in never-smokers (EGFR ~15-40%, ALK fusions ~5-13%, MET ~3-8%) and the PM2.5/air pollutant oxidative stress driving never-smoker lung carcinogenesis, with quercetin from onions confirmed to inhibit cell viability dose-dependently in H1299 (p53-null human large cell lung carcinoma cell line) and A549 lung cancer cells; pro-apoptotic autophagy induced via SIRT1/AMPK signaling confirmed; mitochondria-dependent apoptosis confirmed; LC3-II, beclin 1 upregulated, p62 suppressed confirmed; autophagosomes confirmed by TEM and LC3 immunofluorescence; pAMPK/AMPK ratio elevated confirmed (PMC8088950) — directly in the H1299 large cell lung carcinoma cell line; quercetin AMPK activation restoring the LKB1/STK11-loss autophagic checkpoint in never-smoker LCC; quercetin inhibiting EGFR/PI3K/AKT and STAT3 targeting the EGFR and ALK driver pathways dominant in non-smoker LCC; curcumin from turmeric inhibiting EGFR kinase, STAT3, PI3K/AKT, and NF-kB in lung cancer cell models targeting EGFR-mutant and ALK-rearranged never-smoker LCC; EGCG from green tea inhibiting EGFR by direct ATP-site binding and inhibiting ALK/STAT3 downstream signaling; sulforaphane from cruciferous vegetables activating Nrf2/ARE — directly countering PM2.5/air pollutant/cooking oil fume oxidative DNA damage and ROS generation driving never-smoker lung carcinogenesis; sulforaphane inducing NQO1, HMOX1, and glutathione-S-transferases through Nrf2 in lung epithelial cells; apigenin inhibiting EGFR and STAT3 in lung cancer cell models; dietary fiber producing butyrate/SCFAs inhibiting HDAC targeting epigenetic LKB1/STK11 and CDKN2A promoter silencing in never-smoker LCC.
Research Notes
Non-smoker LCC epidemiology: LCC ~5-10% of all NSCLC; ~11,000-22,000 US cases/year; non-smoker LCC ~15-25% of all LCC; LCINS ~15-25% of all lung cancer worldwide — ~7th most common cancer death globally if counted separately; female predominance in East Asian never-smoker LCC reflecting cooking oil fume exposure; stage III/IV at diagnosis ~60-75%; brain metastasis at diagnosis/disease course ~30-50%. Non-smoker molecular drivers (vs. smoking-related): EGFR mutations ~15-40% (Caucasian) to ~40-60% (East Asian) in never-smokers vs. ~5% in smokers; predominantly exon 19 del and exon 21 L858R; ALK fusions (EML4-ALK predominantly) ~5-13% never-smoker NSCLC vs. <2% smokers; METex14 skipping ~3-8%; RET fusions ~2-4%; ROS1 fusions ~2-3%; ERBB2/HER2 ~2-5%; PIK3CA ~5-10%; STK11/LKB1 ~5-15%; TMB lower in never-smoker LCC (fewer carcinogen-induced mutations); KRAS G12D (vs. G12V in smokers) in a subset; H1299 cell line: p53-null, large cell lung carcinoma, N-ras Q61K, lymph node metastasis origin — most applicable LCC cell line. Non-tobacco risk factors for never-smoker LCC: PM2.5 fine particulate matter; radon alpha particle ionizing radiation; cooking oil fumes (East Asian wok cooking — acrolein, benzopyrene, aldehydes); asbestos; arsenic; second-hand smoke. Quercetin H1299/A549 (PMC8088950): cell viability inhibited CCK-8 dose-dependent; mitochondria-dependent apoptosis Western blot confirmed; LC3-II/beclin 1 upregulated; p62 suppressed; Atg5/Atg7/Atg12 mRNA upregulated RT-PCR; autophagosomes TEM confirmed; LC3 immunofluorescence confirmed; SIRT1 protein elevated dose-dependent; pAMPK/AMPK elevated; 3-MA inhibition abolished quercetin apoptosis; EX527/siRNA SIRT1 knockdown attenuated autophagy — SIRT1/AMPK mechanism confirmed.
Notes Visibility
Key Foods
Turmeric,Broccoli,Kale,Spinach,Brussels Sprouts,Cauliflower,Garlic,Yellow Onion,Carrot,Tomato,Beetroot,Cabbage,Blueberry,Pomegranate,Grape,Raspberry,Apple,Orange,Lemon,Soybeans,Edamame,Green Lentils,Black Beans,Chickpeas,Brown Rice,Quinoa,Oats,Wild Rice,Black Rice,Walnut,Almond,Brazil Nut,Flaxseed,Pumpkin Seeds,Chia Seeds,Sesame Seeds,Hemp Seeds,Shiitake,Maitake,Lions Mane,Cremini,Portobello,Green Tea,Ginger,Black Pepper,Garlic Powder,Parsley,Rosemary,Oregano
, Celery, Fennel, Leek,Avocado,Artichoke,Radish,Parsnip,Tangerine, Red Onion
Linked Nutrients
vitamin-c,vitamin-e,vitamin-a,vitamin-b9,vitamin-b6,selenium,zinc,magnesium,calcium,potassium,iron,quercetin,curcumin,egcg,sulforaphane,beta-carotene,anthocyanins,dietary-fiber,l-theanine,allicin
